John Rim, Samsung Biologics president and CEO (PR Newswire)
Pfizer, Samsung Biologics build on biosimilar deals now worth $897M
Pfizer has expanded upon a pair of agreements with Samsung Biologics to make its biosimilars in a deal worth almost $900 million.
According to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
